Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment

Levetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking

(2015) Elizabeth García-Pérez et al.   EPILEPSIA

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures

(2015) Pavel Klein et al.   EPILEPSIA

Brivaracetam augments short-term depression and slows vesicle recycling

(2015) Xiaofeng Yang et al.   EPILEPSIA

Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action

(2015) Jean-Marie Nicolas et al.   EPILEPSIA

An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam

(2015) Stephen L. Yates et al.   EPILEPSY & BEHAVIOR

Brivaracetam and carbamazepine interaction in healthy subjects and in vitro

(2015) Armel Stockis et al.   EPILEPSY RESEARCH

Brivaracetam Differentially Affects Voltage-Gated Sodium Currents Without Impairing Sustained Repetitive Firing in Neurons

(2014) Isabelle Niespodziany et al.   CNS Neuroscience & Therapeutics

Brivaracetam Single and Multiple Rising Oral Dose Study in Healthy Japanese Participants: Influence of CYP2C19 Genotype

(2014) Armel Stockis et al.   Drug Metabolism and Pharmacokinetics

The Potential of Antiseizure Drugs and Agents that Act on Novel Molecular Targets as Antiepileptogenic Treatments

(2014) Rafal M. Kaminski et al.   Neurotherapeutics

Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays

(2013) V Daniels et al.   BRITISH JOURNAL OF PHARMACOLOGY

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial

(2013) Victor Biton et al.   EPILEPSIA

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial

(2013) Philippe Ryvlin et al.   EPILEPSIA

New avenues for anti-epileptic drug discovery and development

(2013) Wolfgang Löscher et al.   NATURE REVIEWS DRUG DISCOVERY

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial

(2012) Wim Van Paesschen et al.   EPILEPSIA

Patterns of treatment response in newly diagnosed epilepsy

(2012) M. J. Brodie et al.   NEUROLOGY

Predictors of health-related quality of life and costs in adults with epilepsy: A systematic review

(2011) Rod S. Taylor et al.   EPILEPSIA

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

(2011) Michel Gillard et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats

(2010) E.R. Detrait et al.   EPILEPSY RESEARCH

Adjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial

(2010) J. A. French et al.   NEUROLOGY

Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam

(2009) Rafal M. Kaminski et al.   EPILEPSIA

Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture

(2009) Cristina Zona et al.   EPILEPSY RESEARCH

Cognitive Disorders Associated with Epilepsy: Diagnosis and Treatment

(2009) Mar Carreño et al.   NEUROLOGIST

Brivaracetam inhibits spreading depression in rat neocortical slices in vitro

(2009) Doru Georg Margineanu et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission

(2009) Xiao-Feng Yang et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men

(2008) Paul Rolan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A

(2008) A Matagne et al.   BRITISH JOURNAL OF PHARMACOLOGY

SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

(2007) Rafal M. Kaminski et al.   NEUROPHARMACOLOGY